For example, antibody masking of LILRB1 was demonstrated to promote the activation of NK cells from chronic lymphocytic leukemia (CLL) patients, to enhance NK cell proliferation when combined with the immunomodulatory drug lenalidomide and to promote lysis of CLL cells (96). This evidence concerns the gene LILRB1 and B-cell chronic lymphocytic leukemia.